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Abstract
Background There are four distinguishable types of THA
devices in wide use, as deﬁned by the femoral and ace-
tabular bearing surfaces: metal-on-polyethylene (MoP),
ceramic-on-polyethylene (CoP), metal-on-metal (MoM),
and ceramic-on-ceramic (CoC). Metallic head THAs (MoP
and MoM) can potentially induce cardiac toxicity because
cobalt species, generated at the head-neck trunnion, and in
the case of MoM devices, at the articular surface as well,
can be absorbed systemically. However, studies have
provided inconsistent results.
Questions/purposes The purpose of this study was to as-
sess the risk of dilated cardiomyopathy (DCM) or heart
failure (HF) associated with metallic head THAs using data
from the French national health insurance databases.
Methods Between 2008 and 2011 in France, 399,968
patients$ 55 years had a ﬁrst THA. A total of 127,481 were
excluded after we applied the exclusion criteria regarding
arthroplasty and 17,137 as a result of a history of DCM/HF,
recorded in the French national health insurance re-
imbursement databases, between January 1, 2006, and the
date of inclusion. The ﬁnal cohort included 255,350 individ-
uals (43% men; mean age 72 6 9 years). Of them, 93,581
(37%) had been implanted with MoP, 58,095 (23%) with
CoP, 11,298 (4%) with MoM, and 92,376 (36%) with CoC
THAs. Patients were followed until December 2015. Patients
with incident DCM/HF were identiﬁed by a new entitlement
to the long-term disease scheme or a ﬁrst hospitalization with
a diagnosis ofDCMorHF.MoP andCoPTHAs are generally
implanted in old patients, whereas MoM and CoC are mostly
indicated in young, active male patients. Thus, to consider the
speciﬁc indications of the bearing couples, analyses were
separately performed in two distinct subcohorts, one com-
prising patients withMoP or CoP and one comprising patients
withMoMorCoCTHA. In each subcohort, theDCM/HF risk
was compared between patients with metallic head versus
nonmetallic head THAs (MoP versus CoP, MoM versus
CoC). Hazard ratios (adjusted HRs) of incident DCM/HF
were estimated using Cox models adjusted for baseline sex,
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age, THA characteristics (ﬁxation technique with cement, use
of a modular femoral neck), and comorbidities at baseline.
Cox models were stratiﬁed by sex and age.
Results The crude incidence of DCM/HF per 100 person-
years was 2.4 in patients with MoP, 1.8 with CoP, 1.2 with
MoM, and 1.1 with CoC THAs. Overall, metallic head
THAs were associated with a slight increase in DCM/HF
risk (MoP versus CoP: adjusted HR, 1.08; 95% conﬁdence
interval [CI], 1.05-1.12; p < 0.001; MoM versus CoC:
adjusted HR, 1.11; 95% CI, 1.03-1.19; p = 0.007). In the
MoM-CoC subcohort, the risk tended to be more pro-
nounced with MoM versus CoC THAs in women (MoM
versus CoC: adjusted HR, 1.20; 95% CI, 1.07-1.35; p =
0.002) and patients aged $ 75 years (MoM versus CoC:
adjusted HR, 1.16; 95% CI, 1.04-1.29; p = 0.009).
Conclusions Metallic head THAs were associated with
a slightly increased DCM/HF risk, especially with MoM in
women and older patients. Some caveats should be men-
tioned: severity of DCM or HF was not available and re-
sidual confounding cannot be ruled out despite considering
many covariates. Our ﬁndings suggest that cardiac function
should be regularly monitored in patients with metallic
head THAs. Further investigations should be planned on
large international cohorts.
Level of Evidence Level III, therapeutic study.
Introduction
More than 1 million THAs are done every year worldwide
[30]. There are fourmain bearing couples in THAs, depending
on the materials used for the prosthetic head and acetabular
cup: metal-on-polyethylene (MoP), ceramic-on-polyethylene
(CoP), metal-on-metal (MoM), and ceramic-on-ceramic
(CoC). As a result of expected lower wear rate and greater
implant longevity, hard-on-hard bearings, MoM and CoC, are
speciﬁcally indicated in young, active male patients [40].
The health effects of metal-implanted medical devices,
including those used in THA, are a growingmatter of concern
[6]. Cobalt-chromium alloys are largely used to manufacture
metallic head THAs (MoM and MoP) [22, 26, 31]. Fretting
and corrosion at the head-neck trunnion, and in the case of
MoM devices, at the articular surface as well, result in metal
ion release. Cobalt particles can disseminate in the body and
accumulate in the heart [9, 35]. Cobalt cardiac toxicity was
ﬁrst reported in the mid-1960s [23]. More recently, case
reports described heart symptoms consistent with the effects
of cobalt cardiac toxicity in patients with metal prostheses [5,
14, 27]. However, to date, only two epidemiologic studies,
based on small patient samples, have explored the cardiac
effects of MoM hip prostheses [16, 32].
National medicoadministrative databases can help us
assess risk pertaining to uncommon but potentially serious
health effects of arthroplasty such as cardiac complications
from corrosion products, as a result of the large number of
included patients, to the individual recorded data and to the
broad range of available information. In particular, the
power of the French national health insurance information
system is great, and its representativeness is high, because
it almost includes the whole country’s population [2, 25].
We therefore sought to assess the risk of dilated car-
diomyopathy (DCM) or heart failure (HF) associated with
metallic head THAs using data from the French national
health insurance databases.
Patients and Methods
The study was based on the French national health insurance
information system, Syste`me National d’Information Inter-
Re´gimes de l’Assurance Maladie (SNIIRAM) [21, 25, 37].
The SNIIRAM databases have been used in previous epide-
miologic studies [3, 4, 10, 11, 20, 33]. These databases cover >
95% of the French population with various programs based
on the individual’s employment situation. It also includes
students, foreigners, and unemployed individuals. The
SNIIRAM contains records since 2006, with dates, on out-
patient drugs, laboratory tests, and medical devices as well as
reimbursed services and procedures. The databases do not
stipulate the medical indication for each reimbursement but
contain the patients’ demographic, administrative, and medi-
cal details (including severe and costly long-term diseases
[LTDs]with full reimbursement of care) and the date of death.
An anonymous, unique identiﬁer for each patient links
SNIIRAM information to the national hospital discharge da-
tabase (Programme de me´dicalisation des systems d’infor-
mation [PMSI]), which covers all public and private hospitals.
For this study, we obtained approval from the French
data protection agency, the Commission Nationale de
l’Informatique et des Liberte´s. Informed consent was not
required because information was collected anonymously.
Participants
The eligible population was patients$ 55 years of age who
had an initial THA between January 1, 2008, and December
31, 2011, and who were alive at the time of discharge. The
identiﬁcation algorithm for patients with THA has been used
in previous studies [3, 10, 11]. The date of inclusion was the
inpatient admission date for the ﬁrst THA. Patients were
excluded if they had a bilateral THA or underwent the ﬁrst
THA because of hip trauma, received a nontotal hip pros-
thesis, or if data characterizing the prosthesis or the bearing
couple were missing or inconsistent. Patients were also ex-
cluded if they had a history of cardiomyopathy or HF or
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a known cause of DCM/HF [1, 7, 24, 29] recorded in the
SNIIRAM-PMSI databases between January 1, 2006, and
the date of inclusion: myopathy, myocarditis, HIV infection,
Lyme disease, or Chagas disease.
Exposure
The exposure of interest was the bearing couple: MoP,
CoP, MoM, or CoC.
Total hip prosthesis is not recorded as a whole in the
PMSI databases, but each of the component elements is
recorded individually according to its List of Products and
Services (LPS) code. For each patient, various LPS codes
were used to identify the bearing surface of the implanted
prosthesis.
MoP and CoP bearings are common options for THA in
old female patients, whereas MoM and CoC are preferen-
tially used in young, male active patients. Because age and
sex are highly associated with the outcome, it was neces-
sary to compare patients of homogeneous proﬁles, with the
exception of the bearing couple, to study the association
between metallic head THAs and DCM/HF risk. Thus, to
take into consideration the speciﬁc indications of the
bearing couples, we divided the study population into two
distinct subcohorts of comparable patients: one comprising
patients withMoP or CoP and one comprising patients with
MoM or CoC.
Outcome
Patients with incident DCM/HF were identiﬁed by a new
entitlement to the LTD scheme or a ﬁrst hospitalization
with a diagnosis of DCM (International Statistical Classi-
ﬁcation of Diseases, 10th Revision [ICD-10] code I42.0) or
HF (ICD-10 code I50.x) or a diagnosis of a HF compli-
cation (ICD-10 codes I11.0, I11.9, I13.0, I13.1, I13.2,
I13.9, K76.1, J81.x).
Covariates
Sociodemographic characteristics included sex, age at
baseline, and afﬁliation with the Couverture Maladie
Universelle Comple´mentaire (CMUc), a free healthcare
insurance program in France that is available for people
with low annual income [38].
The characteristics of the initial THA were ﬁxation
technique with cement, use of a modular femoral neck, and
other metal medical devices implanted before inclusion
such as a total knee arthroplasty or coronary stent.
Conditions known to be or suspected of being associ-
ated with DCM or HF [1, 7, 24, 28, 29] were considered at
baseline, namely cardiovascular comorbidities, psychiatric
comorbidities, endocrinal and metabolic comorbidities,
other comorbidities, drugs, and lifestyle factors. Cardio-
vascular comorbidities were ischemic cardiovascular dis-
ease, atrial ﬁbrillation, left ventricular hypertrophy,
valvular disease, and high blood pressure. Psychiatric
comorbidities were depression and sleep disorders (using
the reimbursement of prescribed hypnotic drugs as
a proxy). Endocrinal and metabolic comorbidities were
diabetes mellitus, measurable morbid obesity, dyslipide-
mia, other endocrinal diseases (including thyroid dis-
orders), and hemochromatosis. Other comorbidities were
cancer, chronic respiratory disease, sleep apnea, serious
infection, chronic kidney disease, and chronic in-
ﬂammatory conditions (such as rheumatoid arthritis). Drug
reimbursement included prescription-only nonsteroidal
antiinﬂammatory drugs and some psychiatric drugs. Life-
style factors were a measurable history of chronic alco-
holism or tobacco smoking. These conditions were
identiﬁed based on a hospital discharge or LTD diagnosis
recorded between January 1, 2006, and the date of in-
clusion together with, if pertinent, relevant prescriptions,
speciﬁc laboratory tests, reimbursed services, and proce-
dures. Drug treatments were identiﬁed with prescriptions
reimbursed at least six times within 1 year before inclusion.
Duration of Followup
Patients were followed from the date of inclusion to the
date of incident DCM/HF. Those without DCM/HF were
censored on the date of the following events, whichever
came ﬁrst: onset of a known cause of DCM/HF (myopathy,
myocarditis, HIV infection, Lyme disease, Chagas dis-
ease), lost to followup (absence of healthcare re-
imbursement for 18months), death, or December 31, 2015.
The duration of followupwas expected to be long enough
to detect incident DCM/HF; like in previous case reports
[5, 14], cardiac symptoms appeared between 3months and 6
years after implantation of metallic head THAs.
Baseline Characteristics of the Study Population
The eligible population comprised 399,968 patients. First,
127,481 patients were excluded after we applied the ex-
clusion criteria regarding arthroplasty; then 17,137 were
excluded as a result of a history of DCM/HF or having
a known cause of DCM/HF. The ﬁnal cohort included
255,350 individuals (42.7% men; mean patient age 72.06
8.8 years); 93,581 (36.6%) had been implanted with MoP,
58,095 (22.8%) with CoP, 11,298 (4.4%) with MoM, and
92,376 (36.2%) with CoC THA (Fig. 1). The median fol-
lowup was 5.4 years, accounting for 799,037 person-years
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(PYs) in the MoP-CoP subcohort, and 5.7 years, account-
ing for 578,851 PYs in the MoM-CoC subcohort.
We observed disparities between the MoP-CoP (n =
151,676) and MoM-CoC (n = 103,674) subcohorts.
Compared with the MoM or CoC group, patients in the
MoP or CoP group were more likely to be women (49.4%
versus 38.2%; p < 0.001), be older (74.86 8.2 years versus
67.9 6 8.0 years; p < 0.001), and to present with cardio-
vascular comorbidities at baseline, including high blood
pressure (62.4% versus 51.1%; p < 0.001) and ischemic
cardiovascular disease (9.0% versus 6.4%; p < 0.001).
Within each subcohort, we observed slight differences
between patients with metallic and nonmetallic head
THAs. Within the MoP-CoP subcohort, fewer of the
patients with MoP were men (36.3% versus 41.2%; p <
0.001), and these patients were older (75.9 6 8.0 years
versus 73.0 6 8.1 years; p < 0.001) than those with CoP
THAs. Cemented or modular neck MoP THAs were more
common. Patients with MoP THAs had more psychiatric
and cardiovascular comorbidities, except for valvular dis-
ease, which was less frequent in the MoP group. Although
these patients presented less frequently with morbid obe-
sity, we observed no difference among the other endocrinal
or metabolic comorbidities. Cancers, chronic respiratory
diseases, serious infections, chronic kidney diseases, and
chronic inﬂammatory conditions were more common in
patients with MoP THAs. We noted no differences in
lifestyle factors. Within the MoM-CoC subcohort, patients
with MoM THAs were more likely to be men (54.0%
versus 48.9%; p < 0.001) and be younger (67.76 8.1 years
versus 67.9 6 8.0 years; p = 0.020) than those with CoC
THAs. More MoM THAs were cemented or had a modular
neck. Patients with MoM THAs presented more often with
high arterial blood pressure or ischemic cardiovascular
diseases; however, we observed no major differences for
the other cardiovascular comorbidities. Patients with MoM
THAs had lower depression rates. We noted no differences
in the rates of diabetes mellitus, measurable morbid obe-
sity, or dyslipidemia, but other endocrinal diseases, in-
cluding thyroid disorders, were less frequent in the MoM
group. We observed no differences in the other comor-
bidities studied. Patients with MoM THAs were more
likely to have a history of tobacco smoking, but we noted
no difference in rates of chronic alcoholism (Table 1).
Statistical Analysis
We conducted statistical analyses separately for MoP
versus CoP and MoM versus CoC.
Kaplan-Meier curves were plotted and log-rank tests
were performed to compare crude differences in cumula-
tive DCM/HF risk. Hazard ratios (adjusted HRs) and their
95% conﬁdence intervals (CIs) were obtained from mul-
tivariate Cox proportional hazard models adjusted for all
baseline covariates. The proportional hazard assumption
was met, meaning that the effect is constant over time. Cox
models were also stratiﬁed by sex or age. Interactions be-
tween the bearing couple and sex as well as age, in asso-
ciation with DCM/HF, were investigated.
We performed sensitivity analyses. First, two time-
dependent covariates were added to complete Cox models,
Fig. 1 The study ﬂowchart shows the number of included patients and the repartition by
bearing couples. *Patients can present more than one exclusion criterion.
1444 Lassalle et al. Clinical Orthopaedics and Related Research®
Table 1. Baseline characteristics by subcohort
Covariates
MoP-CoP subcohort (n = 151,676) MoM-CoC subcohort (n = 103,674)
MoP
(n = 93,581)
CoP
(n = 58,095)
p
value*
MoM
(n = 11,298)
CoC
(n = 92,376)
p
value*
Sociodemographic
characteristics
Male sex 33,967 (36.3%) 23,920 (41.2%) < 0.001 6104 (54.0%) 45,149 (48.9%) < 0.001
Age (years), mean (SD)
[range]
75.9 (8.0), [55-106] 73.0 (8.1), [55-98] < 0.001 67.7 (8.1), [55-96] 67.9 (8.0), [55-102] 0.020
# 65 11,757 (12.6%) 12,043 (20.7%) 4969 (44.0%) 40,278 (43.6%)
66-75 28,655 (30.6%) 21,790 (37.5%) 4217 (37.3%) 34,279 (37.1%)
> 75 53,169 (56.8%) 24,262 (41.8%) 2112 (18.7%) 17,819 (19.3%)
THA characteristics
THA ﬁxation with cement 41,158 (44.0%) 19,032 (32.8%) < 0.001 3122 (27.6%) 12,788 (13.8%) < 0.001
Modular neck 2089 (2.2%) 1032 (1.8%) < 0.001 780 (6.9%) 3310 (3.6%) < 0.001
Other metallic devices
Total knee arthroplasty 2960 (3.2%) 1809 (3.1%) 0.594 240 (2.1%) 2080 (2.3%) 0.388
Cardiovascular comorbidities
Ischemic cardiovascular
disease
8873 (9.5%) 4837 (8.3%) < 0.001 774 (6.9%) 5830 (6.3%) 0.027
Atrial ﬁbrillation 6508 (7.0%) 3214 (5.5%) < 0.001 466 (4.1%) 3555 (3.9%) 0.151
Valvular disease 3375 (3.6%) 2222 (3.8%) 0.028 244 (2.1%) 2266 (2.5%) 0.056
High arterial blood pressure 59,561 (63.7%) 35,021 (60.3%) < 0.001 5892 (52.2%) 47,055 (50.9%) 0.015
Psychiatric comorbidities
Depression 12,122 (13.0%) 6502 (11.2%) < 0.001 1041 (9.2%) 9558 (10.4%) < 0.001
Sleep disorders 7775 (8.3%) 4449 (7.7%) < 0.001 720 (6.4%) 5974 (6.5%) 0.700
Endocrinal or metabolic
comorbidities
Diabetes mellitus 11,301 (12.1%) 6855 (11.8%) 0.107 1196 (10.6%) 9672 (10.5%) 0.705
Measurable morbid obesity 10,457 (11.2%) 7030 (12.1%) < 0.001 1361 (12.1%) 10,701 (11.6%) 0.148
Dyslipidemia 34,518 (36.9%) 21,225 (36.5%) 0.169 3690 (32.7%) 30,878 (33.4%) 0.103
Other endocrinal diseases 9363 (10.0%) 5737 (9.9%) 0.411 914 (8.1%) 8256 (8.9%) 0.003
Other comorbidities
Cancer 10,132 (10.8%) 5312 (9.1%) < 0.001 832 (7.36%) 7228 (7.8%) 0.085
Chronic respiratory disease 9105 (9.7%) 5252 (9.0%) < 0.001 955 (8.5%) 7473 (8.1%) 0.183
Sleep apnea 2000 (2.1%) 1412 (2.4%) < 0.001 317 (2.8%) 2342 (2.5%) 0.086
Serious infection 12,587 (13.5%) 6341 (10.9%) < 0.001 952 (8.4%) 8189 (8.9%) 0.121
Chronic kidney disease 2078 (2.2%) 1129 (1.9%) < 0.001 108 (1.0%) 940 (1.0%) 0.536
Chronic inﬂammatory
condition
2878 (3.2%) 1513 (2.6%) < 0.001 284 (2.5%) 2066 (2.2%) 0.062
Drug reimbursement
Prescription-only
nonsteroidal
antiinﬂammatory drugs
15,107 (16.1%) 10,339 (17.8%) < 0.001 2086 (18.5%) 18,950 (20.5%) < 0.001
Lifestyle factors
History of chronic alcoholism 1909 (2.0%) 1112 (1.9%) 0.088 258 (2.3%) 1931 (2.1%) 0.178
History of tobacco smoking 6731 (7.2%) 4323 (7.4%) 0.070 975 (8.6%) 7346 (8.0%) 0.012
Only baseline characteristics whose prevalence was $ 2% or over, in one or both subcohorts, are presented in this table.
*Mann-Whitney test for age, chi square tests for the other variables; MoP =metal-on-polyethylene; CoP = ceramic-on-polyethylene;
MoM = metal-on-metal; CoC = ceramic-on-ceramic.
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namely revision surgery with a MoM THA or contralateral
MoM THA during followup, because these procedures
may increase metal exposure. Second, to account for cal-
endar period, Cox proportional hazard models considering
age as the time-scale, and stratiﬁed by birth cohort (in 5-
year intervals), were performed [19, 36]. Third, a pro-
pensity score was calculated for the assignment of either
a metallic head or nonmetallic head THA using inverse
probability of treatment weighted logistic regression
models [18]. Fourth, Fine-Gray models [15] were used to
estimate the association of metallic head THA with the
incidence of DCM/HF with death as the competing event.
Fifth, patients experiencing an outcome within 1 month, 3
months, or 6 months after their ﬁrst THA were excluded,
because these early events could be a marker of preexisting
DCM/HF. Finally, we used a more stringent deﬁnition for
the outcome without identiﬁcation of HF complications:
patients with incident DCM/HF were identiﬁed by a new
entitlement to the LTD scheme or a ﬁrst hospitalization
with a diagnosis of DCM (ICD-10 code I42.0) or HF (ICD-
10 code I50.x).
Statistical tests were two-tailed with 5% a risk. Anal-
yses were performed using SAS Enterprise Guide 4.3
software (SAS Institute, Cary, NC, USA).
Results
DCM/HF Risk in the MoP-CoP Subcohort
Incidence rates of DCM/HF were 2.4/100 PYs in the MoP
group and 1.8/100 PYs in the CoP group (Table 2). Crude
cumulative DCM/HF risk was higher in patients with MoP
than in those with CoP THAs (19.6% and 14.4%, re-
spectively; p < 0.001; Fig. 2).
After controlling for potential confounding variables such
as sex, age, comorbidities at baseline, and implant-related
factors other than the bearing couple itself, MoP THAs were
associated with a slight increase in DCM/HF risk compared
with CoP THAs (adjusted HR, 1.08; 95% CI, 1.05–1.12; p <
0.001). This increased risk associated with MoP THAs was
consistent regardless of sex (men: adjustedHR, 1.07; 95%CI,
1.02–1.12; p = 0.008; women: adjusted HR, 1.09; 95% CI,
1.04–1.14; p < 0.001) and age (# 65 years: adjusted HR,
1.08; 95% CI, 0.94–1.24; p = 0.268; 66-75 years: adjusted
HR, 1.13; 95%CI, 1.05–1.21; p< 0.001; > 75 years: adjusted
HR, 1.14; 95% CI, 1.10–1.18; p < 0.001) (Table 2).
In sensitivity analyses, the HR estimates were consistent
with the main results when adding the two time-dependent
covariates to the model (revision surgery with aMoMTHA
and contralateral MoM THA during followup) (adjusted
HR, 1.08; 95% CI, 1.04–1.11; p < 0.001), accounting for
calendar period (adjusted HR, 1.08; 95% CI, 1.05–1.12; p
< 0.001), adjusting for the propensity score (adjusted HR,
1.06; 95% CI, 1.03–1.10; p < 0.001), or using a Fine-Gray
model (adjusted HR, 1.06; 95% CI, 1.03–1.10; p < 0.001).
Exclusion of patients with events within 1 month (adjusted
HR, 1.08; 95% CI, 1.04–1.11; p < 0.001), 3 months (ad-
justed HR, 1.08; 95% CI, 1.04–1.11; p < 0.001), or 6
months (adjusted HR, 1.07; 95% CI, 1.04–1.11; p < 0.001)
after the date of ﬁrst THA did not modify the HR estimates.
When using more stringent criteria for the outcome (new
entitlement to the LTD scheme or ﬁrst hospitalization with
a diagnosis of DCM [ICD-10 code I42.0] or HF [ICD-10
Table 2. DCM/HF risk associated with MoP versus CoP THA, overall, by sex and by age
Type of analyses
Number of incident DCM/HF (incidence rate per 100 PYs) Multivariate analyses*
MoP CoP HR (95% CI) p value
Overall 11,540 (2.4) 5552 (1.8) 1.08 (1.05-1.12) < 0.001
Stratiﬁed by sex
Men 4817 (2.8) 2676 (2.1) 1.07 (1.02-1.12) 0.008
Women 6723 (2.2) 2876 (1.5) 1.09 (1.04-1.14) < 0.001
Stratiﬁed by age
# 65 years old 441 (0.7) 398 (0.6) 1.08 (0.94-1.24) 0.268
66-75 years old 2102 (1.3) 1428 (1.2) 1.13 (1.05-1.21) < 0.001
> 75 years old 8997 (3.4) 3726 (3.0) 1.14 (1.10-1.18) < 0.001
*Cox models adjusted for: sex and age at baseline, aﬃliation with the CMUc (free healthcare insurance program in France), THA
ﬁxation with cement, use of a modular neck, history of implantation with total knee arthroplasty, coronary stent, ischemic
cardiovascular disease, atrial ﬁbrillation, left ventricular hypertrophy, valvular disease, high blood pressure, depression, sleep
disorders, diabetes mellitus, measurable morbid obesity, dyslipidemia, other endocrinal diseases, hemochromatosis, cancer,
chronic respiratory disease, sleep apnea, serious infection, chronic kidney disease, chronic inﬂammatory condition, reimbursement
of prescription-only nonsteroidal antiinﬂammatory drugs, reimbursement of speciﬁc psychiatric drugs, measurable history of
chronic alcoholism or tobacco smoking; DCM = dilated cardiomyopathy; HF = heart failure; MoP = metal-on-polyethylene; CoP =
ceramic-on-polyethylene; PYs = person-years; HR = hazard ratio; CI = conﬁdence interval.
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code I50.x]), MoP THAs remained associated with a slight
increase in DCM/HF risk compared with CoP THAs (ad-
justed HR, 1.09; 95% CI, 1.05–1.13; p < 0.001; see Table,
Supplemental Digital Content 1).
DCM/HF Risk in the MoM-CoC Subcohort
Incidence rateswere 1.2/100 PYs in theMoMgroup and 1.1/
100 PYs in the CoC group. Crude cumulative DCM/HF risk
was higher in patients with MoM than in those with CoC
THAs (9.9% and 8.7%, respectively; p < 0.001; Fig. 3).
After controlling for potential confounding variables
such as sex, age, comorbidities at baseline, and implant-
related factors other than the bearing couple itself, MoM
THAs were associated with a slight increase in DCM/HF
risk compared with CoC THAs (adjusted HR, 1.11; 95%
CI, 1.03–1.19; p = 0.007). Models stratiﬁed by sex or age
showed that this risk tended to be more pronounced in
women (men: adjusted HR, 1.04; 95% CI, 0.94–1.15; p =
0.429; women: adjusted HR, 1.20; 95% CI, 1.07–1.35; p =
0.002) and among patients > 75 years (# 65 years: adjusted
HR, 1.04; 95% CI, 0.88–1.23; p = 0.634; 66-75 years:
adjusted HR, 1.03; 95% CI, 0.91–1.17; p = 0.658; > 75
years: adjusted HR, 1.16; 95% CI, 1.04–1.29; p = 0.009),
although the interaction tests were not signiﬁcant (Table 3).
In sensitivity analyses, the HR estimates were consistent
when adding the two time-dependent covariates (adjusted
HR, 1.10; 95% CI, 1.02–1.19; p = 0.013), accounting for
calendar period (adjusted HR, 1.09; 95% CI, 1.01–1.18; p =
0.024), adjusting for the propensity score (adjusted HR, 1.08;
95% CI, 1.00–1.17; p = 0.037), or using a Fine-Gray model
(adjusted HR, 1.12; 95% CI, 1.04–1.21; p = 0.004). The HR
estimates were not modiﬁed after excluding patients who had
events within 1 month (adjusted HR, 1.11; 95% CI,
1.03–1.19; p= 0.008), 3months (adjustedHR, 1.11; 95%CI,
1.03–1.20; p = 0.007), or 6 months (adjusted HR, 1.11; 95%
CI, 1.03–1.20; p = 0.007) after the date of their ﬁrst THA.
When using more stringent criteria for the outcome (new
entitlement to the LTD scheme or ﬁrst hospitalization with
a diagnosis ofDCM[ICD-10 code I42.0] orHF [ICD-10 code
I50.x]), the HR estimate of the association between DCM/HF
risk and MoM (versus CoC) THAs remained consistent with
the main results (adjusted HR, 1.01; 95% CI, 0.93-1.10; p =
0.756; see Table, Supplemental Digital Content 2).
Discussion
Metallic head THAs (MoP and MoM) are suspected to be
associated with an increased risk of cardiac toxicity as a result
Fig. 2 The cumulative DCM/HF risk according to the bearing couple in the MoP-CoP sub-
cohort is shown.
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of potential systemic cobalt dissemination related to fretting
and corrosion arising from the head-neck junction and, for the
MoM bearing, from the articular surface as well, although the
reported ﬁndings have been inconsistent [16, 32]. The French
national health insurance databases are a powerful tool to
assess cardiac risk related to metallic head THAs. In this
study, MoP (versus CoP) and MoM (versus CoC) THAs
were associated with a slight increase in incident DCM/HF
Fig. 3 The cumulative DCM/HF risk according to the bearing couple in the MoM-CoC sub-
cohort is shown.
Table 3. DCM/HF risk associated with MoM versus CoC THA, overall, by sex and by age
Type of analyses
Number of incident DCM/HF
(incidence rate per 100 PYs) Multivariate analyses*
MoM CoC HR (95% CI) p value
Overall 815 (1.2) 5379 (1.1) 1.11 (1.03-1.19) 0.007
Stratiﬁed by sex
Men 461 (1.3) 3067 (1.2) 1.04 (0.94-1.15) 0.429
Women 354 (1.1) 2312 (0.9) 1.20 (1.07-1.35) 0.002
Stratiﬁed by age
# 65 years old 156 (0.5) 960 (0.4) 1.04 (0.88-1.23) 0.634
66-75 years old 277 (1.1) 1939 (1.0) 1.03 (0.91-1.17) 0.658
> 75 years old 382 (3.3) 2480 (2.7) 1.16 (1.04-1.29) 0.009
*Cox models adjusted for: sex and age at baseline, aﬃliation with the CMUc (free healthcare insurance programs in France), THA
ﬁxation with cement, use of a modular neck, history of implantation with total knee arthroplasty, coronary stent, ischemic
cardiovascular disease, atrial ﬁbrillation, left ventricular hypertrophy, valvular disease, high blood pressure, depression, sleep
disorders, diabetes mellitus, measurable morbid obesity, dyslipidemia, other endocrinal diseases, hemochromatosis, cancer,
chronic respiratory disease, sleep apnea, serious infection, chronic kidney disease, chronic inﬂammatory condition, reimbursement
of prescription-only nonsteroidal antiinﬂammatory drugs, reimbursement of speciﬁc psychiatric drugs, measurable history of
chronic alcoholism or tobacco smoking; DCM = dilated cardiomyopathy; HF = heart failure; MoM =metal-on-metal; CoC = ceramic-
on-ceramic; PYs = person-years; HR = hazard ratio; CI = conﬁdence interval.
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risk overall. The risk tended to be more pronounced with
MoM (versus CoC) THAs in women and patients aged
$ 75 years.
Some limitations should be mentioned. First, this study
showed a moderate effect size of the association between
DCM/HF risk and metallic head THAs. These ﬁndings
have public health relevance, however, as a result of the
large and increasing number of implanted patients and the
severity of the studied cardiac events. Overall, multiple
sensitivity analyses were performed, showing results con-
sistent with those in the main analyses, thus supporting the
robustness of the ﬁndings. Although absolute risks were
not different when using a restrictive deﬁnition of the
outcome, the observed effect between DCM/HF risk and
metallic head THAs was consistent with the main results
with CIs overlapping. Absolute risks were not different in
some subgroups either, in particular in patients aged 55 to
65 years, potentially as a result of an absence of an asso-
ciation in this population or as a result of a lack of power in
this subgroup. Further investigations based on large in-
ternational cohorts, with powered subgroups analyses, are
needed to conﬁrm our results about the association between
DCM/HF risk and metallic head THAs. Second, the out-
come was identiﬁed either by a new entitlement to the LTD
scheme or a ﬁrst hospitalization with a diagnosis of DCM,
HF, or HF complication. Thus, our analyses focused on the
most serious cases of DCM/HF. Moreover, changes in
coding patterns of DCM/HF in discharge diagnoses, cod-
ing errors, or inappropriate coding practices could have
occurred over time. However, such changes are likely to
have occurred regardless of THA bearing couple and
therefore are not expected to have biased our results. Third,
although many confounding factors were considered, in-
cluding the use of a modular femoral neck or revision with
aMoMTHA, the confounding effect of unmeasured and/or
unknown risk factors of DCM/HF cannot be ruled out.
Information on dietary, occupational, or environmental
exposure to cobalt was not available. However, these fac-
tors were not expected to inﬂuence the choice of the
bearing couple. MoM prostheses are suspected of inducing
greater blood metal concentrations than MoP [8, 34, 39].
But biologic cobalt levels, when performed, were not
recorded. Finally, causes of death were not available in the
French national health insurance databases.
Previous epidemiologic studies have suggested an
association between MoM THAs and cardiac toxicity.
In a single-center, cross-sectional study based on 35
matched pairs of patients in the United Kingdom (31 men,
four women), Prentice et al. [32] found a 7% lower car-
diac ejection fraction in the MoM hip resurfacing group
versus non-MoM THAs. Although they observed no
difference in the New York Heart Association score for
HF, that study was not powered to evaluate cardiac end-
points, which were assessed as a secondary outcome. In
a cohort study using data from the Australian Government
Department of Veterans’ Affairs health claims database,
Gillam et al. [16] found that, in men, Articular Surface
Replacement XL large femoral head MoM THAs (DePuy
Orthopaedics Inc, Warsaw, IN, USA) were associated
with a higher rate of hospitalization for HF compared with
MoP THAs with an adjusted HR of 3.21 (95% CI, 1.59-
6.47). They found no difference in women, but, according
to the authors, the male cohort was a more vulnerable
group and as such was more susceptible to development
of HF after exposure to MoM prostheses than the female
cohort. Moreover, the choice of a potentially cardiotoxic
comparator, MoP THA, could have led to an un-
derestimation of the risk. In the present study, the DCM/
HF risk tended to be more pronounced with MoM THAs
compared with CoC in women and patients > 75 years.
Theories about pharmacokinetic and immunologic fac-
tors may explain this ﬁnding. Sex and age differences in
the metabolism of metal ions (such as different lean mass,
cellular or extracellular storage, or renal excretion) may
lead to higher metal levels in women [13] and in older
individuals. In addition, an increased incidence of metal
allergy has been observed in women [17] and is known to
be involved in local reactions around the hip prosthesis
[12]. However, to date, there is little evidence that metal
hypersensitivity could contribute to cardiac toxicity.
This study showed a slightly increased DCM/HF risk
associated with metallic head THAs, especially in women
and older patients. Although moderate in size, these
results have public health relevance as a result of the large
and increasing number of implanted patients and to the
severity of these cardiac events. Our ﬁndings suggest that
cardiac function should be regularly monitored in patients
with metallic head THAs. Moreover, occurrence of car-
diac symptoms in patients with metallic head THAs
should alert the physician to potential toxicity related to
cobalt exposure. Further investigations on the potential
harmful effects of metallic exposure related to medical
devices should be considered in future research through
international consortiums that integrate epidemiologic
data from multiple sources.
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